Small molecule-based inhibitors for treatment of tick-borne encephalitis virus infection: Nucleoside analogs and nonnucleoside antivirals

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F22%3AN0000251" target="_blank" >RIV/00027162:_____/22:N0000251 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60077344:_____/22:00569226

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/abs/pii/S0065774322000033?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S0065774322000033?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/bs.armc.2022.08.003" target="_blank" >10.1016/bs.armc.2022.08.003</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Small molecule-based inhibitors for treatment of tick-borne encephalitis virus infection: Nucleoside analogs and nonnucleoside antivirals

Popis výsledku v původním jazyce

More than 10,000 people a year become infected with TBEV, in which many cases are fatal. Despite the considerable medical importance of TBE, there is currently no approved antiviral treatment available to cure TBEV infections. Therefore, development of highly efficient and safe anti-TBEV drugs is an urgent medical need. Currently, numerous small molecule-based drugs are used to combat long-lasting/chronic viral infections, including those caused by HIV, HBV, HCV or HSV. Many of these antivirals, showing anti-TBEV activities, could be repurposed for the treatment of TBEV infections. However, it should be noted that small molecule-based treatments of acute viral infection, including TBE, could be somewhat challenging, as the serious/life-threatening symptoms of acute infections are very often a consequence of both viral replication in the host cells/tissues and the proinflammatory immune response combined with cytokine storms. The solution to this problem could be solved by a combination or sequential therapy based on application of both direct-acting antivirals, as well as antiinflammatory agents. Together with effective vaccination strategies specific small molecule-based therapy could provide a potent prophylactic and curative tools to combat human infections caused by TBEV.

Název v anglickém jazyce

Small molecule-based inhibitors for treatment of tick-borne encephalitis virus infection: Nucleoside analogs and nonnucleoside antivirals

Popis výsledku anglicky

More than 10,000 people a year become infected with TBEV, in which many cases are fatal. Despite the considerable medical importance of TBE, there is currently no approved antiviral treatment available to cure TBEV infections. Therefore, development of highly efficient and safe anti-TBEV drugs is an urgent medical need. Currently, numerous small molecule-based drugs are used to combat long-lasting/chronic viral infections, including those caused by HIV, HBV, HCV or HSV. Many of these antivirals, showing anti-TBEV activities, could be repurposed for the treatment of TBEV infections. However, it should be noted that small molecule-based treatments of acute viral infection, including TBE, could be somewhat challenging, as the serious/life-threatening symptoms of acute infections are very often a consequence of both viral replication in the host cells/tissues and the proinflammatory immune response combined with cytokine storms. The solution to this problem could be solved by a combination or sequential therapy based on application of both direct-acting antivirals, as well as antiinflammatory agents. Together with effective vaccination strategies specific small molecule-based therapy could provide a potent prophylactic and curative tools to combat human infections caused by TBEV.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

10607 - Virology

Projekt

<a href="/cs/project/LTAUSA18016" target="_blank" >LTAUSA18016: Výzkum nových nukleosidových analogů jako antivirotik proti medicínsky významným flavivirům</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Annual Reports in Medicinal Chemistry

ISBN

978-0-323-98893-3

Počet stran výsledku

38

Strana od-do

55-92

Počet stran knihy

268

Název nakladatele

Academic Press

Místo vydání

USA, UK

Kód UT WoS kapitoly

—